Chinook Therapeutics, Inc. financial data

Industry
Pharmaceutical Preparations
Location
400 Fairview Avenue North, Suite 900, Seattle, Washington
State of incorporation
Delaware
Fiscal year end
December 31
Former names
ADURO BIOTECH, INC. (to 10/15/2020), ADURO BIOTECH (to 4/22/2011)
Latest financial report
Q2 2023 - Aug 7, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 719 % -18.5%
Debt-to-equity 30.3 % +19%
Return On Equity -58.3 % -161%
Return On Assets -44.7 % -151%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 71.8 M shares +14.2%
Common Stock, Shares, Outstanding 67.1 M shares +6.69%
Entity Public Float 896 M USD +94.8%
Common Stock, Value, Issued 7 K USD +16.7%
Weighted Average Number of Shares Outstanding, Basic 71.6 M shares +15.5%
Weighted Average Number of Shares Outstanding, Diluted 71.6 M shares +15.5%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 5.85 M USD -89.2%
Research and Development Expense 194 M USD +84.9%
General and Administrative Expense 44.3 M USD +42.3%
Operating Income (Loss) -252 M USD -192%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -184 M USD -82%
Income Tax Expense (Benefit) 4.34 M USD +53.2%
Net Income (Loss) Attributable to Parent -246 M USD -166%
Earnings Per Share, Basic -3.56 USD/shares -54.1%
Earnings Per Share, Diluted -3.56 USD/shares -54.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 127 M USD -12.9%
Marketable Securities, Current 170 M USD -21.5%
Assets, Current 305 M USD -17.8%
Property, Plant and Equipment, Net 16.2 M USD -7.23%
Operating Lease, Right-of-Use Asset 42.9 M USD -18%
Intangible Assets, Net (Excluding Goodwill) 60 M USD -2.8%
Goodwill 117 K USD 0%
Other Assets, Noncurrent 14.2 M USD +101%
Assets 489 M USD -18.7%
Accounts Payable, Current 16.4 M USD +233%
Liabilities, Current 52.5 M USD +78%
Deferred Income Tax Liabilities, Net 5.08 M USD +591%
Operating Lease, Liability, Noncurrent 29.7 M USD -20%
Liabilities 132 M USD +40%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1.33 M USD +47.6%
Retained Earnings (Accumulated Deficit) -547 M USD -81.6%
Stockholders' Equity Attributable to Parent 357 M USD -29.6%
Liabilities and Equity 489 M USD -18.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -50.7 M USD -105%
Net Cash Provided by (Used in) Financing Activities 21.3 M USD +1106%
Net Cash Provided by (Used in) Investing Activities 32.4 M USD
Common Stock, Shares Authorized 300 M shares 0%
Common Stock, Shares, Issued 67.1 M shares +6.69%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3.06 M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 129 M USD -12.7%
Deferred Tax Assets, Valuation Allowance 98.7 M USD +65.2%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 127 M USD +66.2%
Operating Lease, Liability 34 M USD -18.8%
Payments to Acquire Property, Plant, and Equipment 927 K USD +148%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -244 M USD -157%
Lessee, Operating Lease, Liability, to be Paid 42.2 M USD -21.1%
Property, Plant and Equipment, Gross 25.8 M USD +11.7%
Operating Lease, Liability, Current 4.27 M USD -9.21%
Lessee, Operating Lease, Liability, to be Paid, Year Two 6.71 M USD -14.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 6.59 M USD -14.4%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Deferred Income Tax Expense (Benefit) -4.34 M USD -107%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 8.19 M USD -29.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 6.71 M USD -16.3%
Deferred Tax Assets, Operating Loss Carryforwards 75.6 M USD +40.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10 M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 6.48 M USD -9.42%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 1.73 M USD +1.59%
Deferred Tax Assets, Net of Valuation Allowance 28 M USD +69.7%
Share-based Payment Arrangement, Expense 28.1 M USD +78.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%